| Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo AV Lee, JG Jackson, JL Gooch, SG Hilsenbeck, E Coronado-Heinsohn, ... Molecular endocrinology 13 (5), 787-796, 1999 | 447 | 1999 |
| p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer JG Jackson, V Pant, Q Li, LL Chang, A Quintás-Cardama, D Garza, ... Cancer cell 21 (6), 793-806, 2012 | 343 | 2012 |
| Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells AV Lee, CN Weng, JG Jackson, D Yee Journal of Endocrinology 152 (1), 39-47, 1997 | 255 | 1997 |
| Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. RL Rocha, SG Hilsenbeck, JG Jackson, CL VanDenBerg, C Weng, ... Clinical cancer research: an official journal of the American Association …, 1997 | 234 | 1997 |
| Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human … JG Jackson, MF White, D Yee Journal of Biological Chemistry 273 (16), 9994-10003, 1998 | 222 | 1998 |
| p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts JG Jackson, OM Pereira-Smith Cancer research 66 (17), 8356-8360, 2006 | 215 | 2006 |
| SASP: tumor suppressor or promoter? Yes! SG Rao, JG Jackson Trends in cancer 2 (11), 676-687, 2016 | 188 | 2016 |
| FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter SK Durham, A Suwanichkul, AO Scheimann, D Yee, JG Jackson, FG Barr, ... Endocrinology 140 (7), 3140-3146, 1999 | 184 | 1999 |
| Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines JG Jackson, X Zhang, T Yoneda, D Yee Oncogene 20 (50), 7318-7325, 2001 | 164 | 2001 |
| Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity HA Abbas, DR Maccio, S Coskun, JG Jackson, AL Hazen, TM Sills, ... Cell stem cell 7 (5), 606-617, 2010 | 153 | 2010 |
| Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation Y Wang, YA Suh, MY Fuller, JG Jackson, S Xiong, T Terzian, ... The Journal of clinical investigation 121 (3), 893-904, 2011 | 142 | 2011 |
| Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as as inhibitor of insulin-like growth factor action WL McGuire Jr, JG Jackson, JA Figueroa, S Shimasaki, DR Powell, D Yee JNCI: Journal of the National Cancer Institute 84 (17), 1336-1341, 1992 | 136 | 1992 |
| Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells JG Jackson, OM Pereira-Smith Molecular and cellular biology 26 (7), 2501-2510, 2006 | 129 | 2006 |
| Multiple Stress Signals Activate Mutant p53 In Vivo YA Suh, SM Post, AC Elizondo-Fraire, DR Maccio, JG Jackson, ... Cancer research 71 (23), 7168-7175, 2011 | 128 | 2011 |
| Blockade of epidermal growth factor-or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects JG Jackson, P St. Clair, MX Sliwkowski, MG Brattain Cancer research 64 (7), 2601-2609, 2004 | 125 | 2004 |
| TP53 mutations and outcomes in breast cancer: reading beyond the headlines A Shahbandi, HD Nguyen, JG Jackson Trends in cancer 6 (2), 98-110, 2020 | 122 | 2020 |
| A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development SM Post, A Quintás-Cardama, V Pant, T Iwakuma, A Hamir, JG Jackson, ... Cancer cell 18 (3), 220-230, 2010 | 121 | 2010 |
| Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential JG Jackson, T Yoneda, GM Clark, D Yee Clinical Cancer Research 6 (3), 1135-1139, 2000 | 118 | 2000 |
| Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells JG Jackson, JI Kreisberg, AP Koterba, D Yee, MG Brattain Oncogene 19 (40), 4574-4581, 2000 | 112 | 2000 |
| Expression of insulin‐like growth factor binding proteins in human breast cancer correlates with estrogen receptor status JA Figueroa, JG Jackson, WL McGuire, RF Krywicki, D Yee Journal of cellular biochemistry 52 (2), 196-205, 1993 | 108 | 1993 |
